Will Genentech's Cotellic Survive Alternative Pricing Demands?
This article was originally published in Scrip
Genentech Inc.'s and Exelixis Inc.'s Cotellic (cobimetinib), a MEK inhibitor, made it across the FDA's finish line on Nov. 10, but now the firms must confront the ultimate test of the drug's success – selling it, which is increasingly becoming more difficult in a climate where payers are becoming more and more demanding about using alternative pricing arrangements.
You may also be interested in...
Shares in Array Biopharma shot up by more than 80% on the release of top-line Phase III data from its COLUMBUS study of encorafenib and binimetinib, but more details are needed to gauge how the combination may fare against Novartis and Roche’s more established combos, and the newer IO therapies.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.